New cancer clinical trial: Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)

Published on: December 25, 2017 at 10:00AM
Condition:   Gastric Cancer
Interventions:   Biological: Pembrolizumab;   Drug: Oxaliplatin;   Drug: TS-1;   Drug: Cisplatin
Sponsor:   Merck Sharp & Dohme Corp.
Not yet recruiting
http://ift.tt/2DX6Qzz